Caitlin MooreinZS AssociatesWhy Leonardo da Vinci would have loved ASCO 2024In the intricate dance between art and science within medicine, particularly in oncology, achieving equilibrium is no small feat.Jun 26
Richard A MeyerWhat won’t be discussed at ASCOThe NIH identified 273 drugs in a review of FDA oncologic drug approvals. After applying exclusion criteria, 224 cancer drug approvals…May 31
Binaytara FoundationConference Co-Chair Spotlight — Best of ASCO Boise 2023Dr. Mark Lewis and Dr. Christos Vaklavas co-chair BTF’s officially licensed Best of ASCO Boise, IDJul 25, 2023Jul 25, 2023
Lifecare newsinLifeCareNewsSutro Biopharma Announces Oral Presentation at ASCO 2023Jun 3, 2023Jun 3, 2023
Caitlin MooreinZS AssociatesWhy Leonardo da Vinci would have loved ASCO 2024In the intricate dance between art and science within medicine, particularly in oncology, achieving equilibrium is no small feat.Jun 26
Richard A MeyerWhat won’t be discussed at ASCOThe NIH identified 273 drugs in a review of FDA oncologic drug approvals. After applying exclusion criteria, 224 cancer drug approvals…May 31
Binaytara FoundationConference Co-Chair Spotlight — Best of ASCO Boise 2023Dr. Mark Lewis and Dr. Christos Vaklavas co-chair BTF’s officially licensed Best of ASCO Boise, IDJul 25, 2023
The Leukemia & Lymphoma SocietyHighlights from ASCO 2021By Lee Greenberger, PhD, LLS Chief Scientific OfficerJun 17, 2021
Pranjal MaheshwariPerspective Future of Architectural EducationDemystifying the CoA reportFeb 22, 20212
Conquer Cancer, the ASCO FoundationCoping with Uncertainty and Fear in the Cancer CommunityBy Howard A. Burris III, MD, FACP, FASCO; Thomas G. Roberts, Jr., MD, FASCO; Clifford A. Hudis, MD, FACP, FASCOApr 13, 2020